1
|
Transarterial Chemoembolization with Doxorubicin Eluting Beads for Extra-Abdominal Desmoid Tumors: Initial Experience. Cardiovasc Intervent Radiol 2022; 45:1141-1151. [PMID: 35441242 PMCID: PMC9400546 DOI: 10.1007/s00270-022-03149-4] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/14/2021] [Accepted: 04/04/2022] [Indexed: 11/02/2022]
Abstract
PURPOSE To evaluate the feasibility, efficacy, and safety of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) as an alternative local treatment for extra-abdominal desmoid tumors (DTs). METHODS Eleven adult female patients (mean age = 40.1 years) with symptomatic, progressively enlarging extra-abdominal DTs were determined ineligible for cryoablation after failing observation or systemic therapy and treated with a single session doxorubicin DEB-TACE. Six rectus sheath, one chest wall, three axilla, and one upper extremity DTs were included. The median follow-up was 155.0 ± 52.3 days. Treatment response was assessed by MRIs and maximum visual analog scale (VAS). RESULTS All procedures were technically successful without immediate complications. The average size of treated DT was 161.8 ml (range: 28.3-420.0 ml). The mean doxorubicin dose was 13.3 mg/m2. All patients experienced skin changes which improved over time without treatments. No higher-grade adverse events were observed. Initial one-month follow-up MRI demonstrated partial to near-complete tumor necrosis, ranging from 1.4 to 97.6% (mean: 36.4%). Additional follow-up revealed a further reduction of overall tumor volume (mean: - 38.1%, p < 0.0001) and maximum VAS (mean: - 2.6, p = 0.0026) in 10 out of 11 patients (90.9%). After the first month, the residual tumors exhibited continued volume reduction in 10 out of 11 patients (mean: - 16.5%, p = 0.0230). There was also a significant decrease of T2 signal intensity within residual tumor on the latest follow-up (mean: - 29.6%, p = 0.0217), suggesting a reduction in tumor cellularity. CONCLUSION DEB-TACE may be a safe and effective local treatment alternative in DT patients.
Collapse
|
2
|
Ruiz I, Maalouf NS, Bentridi A, Holderbaum do Amaral R, Olivié D, Perreault P, Fenyves D, Hill A, Bouchard L. Abdominal Skin Injury due to Non-Target Embolization of Hepatocellular Carcinoma Vascularized by the Internal Mammary Artery. Cardiovasc Intervent Radiol 2021; 45:142-146. [PMID: 34476579 DOI: 10.1007/s00270-021-02951-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/27/2021] [Accepted: 08/16/2021] [Indexed: 11/28/2022]
Affiliation(s)
- Isaac Ruiz
- Department of Hepatology and Liver Transplantation, Centre Hospitalier de l'Université de Montréal (CHUM), 1051 rue Sanguinet, Montréal, Qc, H2X 0C1, Canada. .,Institut Mondor de Recherche Biomédicale (IMRB), Université Paris-Est, Hôpital Henri Mondor, INSERM U955 Team 18, Créteil, France.
| | - Nadine S Maalouf
- Department of Dermatology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Canada
| | - Ahmed Bentridi
- Department of Radiology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Canada
| | | | - Damien Olivié
- Department of Radiology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Canada
| | - Pierre Perreault
- Department of Radiology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Canada
| | - Daphna Fenyves
- Department of Hepatology and Liver Transplantation, Centre Hospitalier de l'Université de Montréal (CHUM), 1051 rue Sanguinet, Montréal, Qc, H2X 0C1, Canada
| | - Ashley Hill
- Department of Dermatology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Canada
| | - Louis Bouchard
- Department of Radiology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Canada
| |
Collapse
|
3
|
Yanagie H, Fujino T, Yanagawa M, Terao T, Imagawa T, Fujihara M, Morishita Y, Mizumachi R, Murata Y, Dewi N, Ono Y, Ikushima I, Seguchi K, Nagata M, Nonaka Y, Furuya Y, Hisa T, Nagasaki T, Arimori K, Nakashima T, Sugihara T, Kakimi K, Ono M, Nakajima J, Eriguchi M, Higashi S, Takahashi H. Tumor Growth Suppression With Novel Intra-arterial Chemotherapy Using Epirubicin-entrapped Water-in-oil-in-water Emulsion In Vivo. In Vivo 2021; 35:239-248. [PMID: 33402470 DOI: 10.21873/invivo.12252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2020] [Revised: 10/18/2020] [Accepted: 10/19/2020] [Indexed: 11/10/2022]
Abstract
BACKGROUND/AIM A mixture of anticancer agents and iodized poppy seed oil (IPSO) has been widely used for intra-arterial chemotherapy of hepatocellular carcinoma. However, the anticancer agents can easily separate from IPSO, so the therapeutic potential is limited. We developed epirubicin-entrapped water-in-oil-in-water emulsion (WOW-Epi) using a double-membrane emulsification technique. MATERIALS AND METHODS We delivered WOW-Epi through a hepatic arterial injection to VX2 hepatic tumor rabbit model (1.2 mg/kg). RESULTS VX2 tumor growth was selectively suppressed in the WOW-Epi-treated group compared with the control treated groups. The accumulation of WOW in nearby cancer cells was confirmed via electron-microscopy. Endocytosis seemed to be the mechanism underlying the uptake of WOW. CONCLUSION WOW-Epi led to tumour growth suppression in vivo. WOW does not cause toxicity to arterial vessels. WOW-Epi will be hopefully used for repeated intra-arterial chemotherapy to HCC patients in the near future.
Collapse
Affiliation(s)
- Hironobu Yanagie
- Institute of Engineering Innovation, School of Engineering, The University of Tokyo, Tokyo, Japan; .,Cooperative Unit of Medicine and Engineering, The University of Tokyo Hospital, Tokyo, Japan.,Research Institute of Healthy Living, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Japan
| | - Takashi Fujino
- Department of Pathology, Saitama Medical University International Medical Center, Hidaka, Japan
| | - Masashi Yanagawa
- Veterinary Medical Center, Obihiro University of Agriculture and Veterinary Medicine, Hokkaido, Japan
| | - Toshimitsu Terao
- Department of Pharmaceutical Technology, Otsuka Pharmaceutical Factory, Tokushima, Japan
| | - Takashi Imagawa
- Department of Chemical Science and Engineering, Graduate School of Engineering, Kobe University, Hyogo, Japan
| | | | - Yasuyuki Morishita
- Department of Human and Molecular Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Ryouji Mizumachi
- Department of Pharmacology, Kumamoto Institute Branch, LSI Medience Ltd. Co., Kumamoto, Japan
| | - Yuuji Murata
- Department of Pharmacology, Kumamoto Institute Branch, LSI Medience Ltd. Co., Kumamoto, Japan
| | - Novriana Dewi
- Laboratory of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Japan
| | - Yuuya Ono
- SPG Techno Ltd. Co., Miyazaki Techno Research Park, Miyazaki, Japan
| | - Ichiro Ikushima
- Department of Radiology, Miyakonojo Shigun Ishikai Hospital, Miyazaki, Japan.,Kyushu Medical Resource Foundation, Miyazaki, Japan
| | - Koji Seguchi
- Department of Surgery, Kojin-kai Medical City East Hospital, Miyazaki, Japan
| | - Masashi Nagata
- Department of Pharmacy, Medical Hospital, Tokyo Medical and Dental University, Tokyo, Japan
| | - Yasumasa Nonaka
- Department of Surgery, Keiai-kai Houyou Hospital, Iwate, Japan
| | - Yoshitaka Furuya
- Department of Surgery, Sodegaura Satukidai Hospital, Chiba, Japan
| | - Tomoyuki Hisa
- Tokyo Bunkyo Study Center, The Open University of Japan, Tokyo, Japan
| | - Takeshi Nagasaki
- Department of Bioengineering, Osaka City University Graduate school of Engineering, Osaka, Japan
| | - Kazuhiko Arimori
- Department of Pharmacy, Miyazaki Medical University Hospital, Miyazaki, Japan
| | | | - Takumichi Sugihara
- Laboratory of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Japan
| | - Kazuhiro Kakimi
- Department of Immunotherapeutics, The University of Tokyo Hospital, Tokyo, Japan
| | - Minoru Ono
- Cooperative Unit of Medicine and Engineering, The University of Tokyo Hospital, Tokyo, Japan.,Department of Cardiovascular Surgery, The University of Tokyo Hospital, Tokyo, Japan
| | - Jun Nakajima
- Cooperative Unit of Medicine and Engineering, The University of Tokyo Hospital, Tokyo, Japan.,Department of Thoracic Surgery, The University of Tokyo Hospital, Tokyo, Japan
| | - Masazumi Eriguchi
- Department of Surgery, Shin-Yamanote Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan
| | - Shushi Higashi
- Kyushu Medical Resource Foundation, Miyazaki, Japan.,Department of Surgery, Kojin-kai Medical City East Hospital, Miyazaki, Japan
| | - Hiroyuki Takahashi
- Institute of Engineering Innovation, School of Engineering, The University of Tokyo, Tokyo, Japan.,Cooperative Unit of Medicine and Engineering, The University of Tokyo Hospital, Tokyo, Japan
| |
Collapse
|